Mass Balance Recovery, Absorption, Metabolism, and Excretion of [14C]Acoziborole in Healthy Male Subjects after Single Microtracer Oral Dosing I – Preparation of GMP [14C]Acoziborole Drug Substance

Acoziborole, an oxaborole-6 carboxamide, is being developed as an oral single dose treatment for Human African trypanosomiasis (also called "sleeping sickness"). As part of the overall development programme, the mass balance, pharmacokinetics, metabolism and excretion of acoziborole were studied in an open-label, clinical phase 1 study in six healthy male subjects. This poster describes the radiolabelling and purification of [14C]acoziborole as a GMP radiolabelled drug substance to support the human metabolism investigation. 

This is part of a series of 3 posters presented at ISSX 2024: 

Investigation of the Matabolite Profile of Acoziborole in Plasma Urine and Fecal Homogenate Samples Using UPLC-MS Fractionation Followed by AMS Analysis | Quotient Sciences

A Single Dose Study to Assess the Mass Balance Recovery, Absorption, Metabolism, and Excretion of [14C]-Acoziborole in Healthy Male Subjects After Oral Dosing | Quotient Sciences